Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of ATRX and DAXX in pancreatic neuroendocrine tumors: Association with recurrence risk, cellular phenotype, and heterogeneity.

Human pathology - 1 Aug 2024

Yasunaga Yoichi, Tanaka Mariko, Arita Junichi, Hasegawa Kiyoshi, Ushiku Tetsuo

Abstract excerpt

Pancreatic neuroendocrine tumors (PanNETs) comprise a heterogeneous group of neoplasms in terms of biological behavior. This study aims to develop a practical algorithm based on emerging biomarkers, including chromatin-remodeling molecules DAXX/ATRX/H3K36me3, in conjunction with established prognostic factors, such as WHO grade and size. In immunohistochemical analyses, 18 of the 111 (16.2%) primary PanNETs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adaptor Proteins, Signal Transducing
Share to Co-Repressor Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Chaperones

Share to Neoplasm Grading

Share to Neoplasm Recurrence, Local

Share to Neuroendocrine Tumors

Share to Pancreatic Neoplasms

Share to X-linked Nuclear Protein

Source

Identifiers

PMID: 38909708
DOI: 10.1016/j.humpath.2024.06.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of ATRX and DAXX in pancreatic neuroendocrine tumors: Association with recurrence risk, cellular phenotype, and heterogeneity.PMID 38909708Read ↗

Immunohistochemistry based molecular subtyping of pancreatic neuroendocrine tumor correlates with clinicopathological outcome: A single institute retrospective studySemantic proximity Read ↗

DAXX is associated with early recurrence of pancreatic neuroendocrine tumors after R0 resection.Semantic proximity Read ↗

Clinicopathological and molecular determinants of pancreatic neuroendocrine tumors: toward precision risk stratification.Semantic proximity Read ↗

Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine TumorsSemantic proximity Read ↗

Insights into Epigenetic Changes Related to Genetic Variants and Cells-of-Origin of Pancreatic Neuroendocrine Tumors: An Algorithm for Practical WorkupSemantic proximity Read ↗

Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.Semantic proximity Read ↗

ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroupSemantic proximity Read ↗

DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumorsSemantic proximity Read ↗

DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association.Semantic proximity Read ↗

Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.Semantic proximity Read ↗

Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the FutureSemantic proximity Read ↗

Genetic and epigenetic drivers of neuroendocrine tumours (NET)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.